RLN2 and neoplasm: Unlike the SU86.86 subcutaneous tumors, the Capan-1 and BxPC-3 subcutaneous tumor models—with histologies more closely resembling human pancreatic cancer—did not show improved antitumor efficacy with RLN2-secreting CAR-T cell therapy.